Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

951.58 +13.97 (+1.49%)
Streaming Delayed Price Updated: 2:03 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
The QQQ Was Hammered Again Today. Here's Why.
U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks. 
Via Benzinga
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
Tesla, Qualcomm Plummet, Lead QQQ Sharply Lower Monday
The Nasdaq and companies in the broader technology sector were trading lower Monday amid profit-taking and overall weakness in the sector. Here&rsq... 
Via Benzinga
Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed. 
Via Talk Markets
Exposures COVID-19
ARKK Stocks Breakdowns and Bounces
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today. 
Via Talk Markets
Return On Capital Employed Overview: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. Sales, however, increased by 4.37% over the previous quarter to $2.53 billion. Despite the... 
Via Benzinga
Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript
REGN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study
Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular... 
Via Benzinga
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... 
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Return On Capital Employed
Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. Sales, however, increased... 
Via Benzinga
Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss
The big biotech delivered impressive revenue and earnings growth. 
Via The Motley Fool
Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed... 
Via Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 49.... 
Via Benzinga
Regeneron Earnings Top, Biotech Giant Edges Higher
Regeneron earnings comfortably beat Q1 views while sales were in line. The biotech giant edged higher before Thursday's open. 
Via Investor's Business Daily
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for... 
Via Benzinga
Exposures COVID-19
Cathie Wood Loaded Up Further On Skillz On Earnings Day
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $52.1 million, in Skillz Inc (NYSE: SKLZ) ahead of the mobile gaming company’s first-... 
Via Benzinga
Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD — Also Adds Skillz
Cathie Wood-led Ark Investment Management on Monday bought more shares of Pinduoduo Inc (NASDAQ: PDD) and JD.com Inc (NASDAQ: JD) — rivals to Alibaba Group Holding (... 
Via Benzinga
Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study
Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted... 
Via Benzinga
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap... 
Via Talk Markets
Exposures COVID-19
Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla
Cathie Wood-led Ark Investment Management bought a total of 716,269 shares, worth about $122.38 million, in Teladoc Health Inc (NYSE: TDOC) on Thursday as the stock slumped after... 
Via Benzinga
Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its... 
Via Benzinga
Topics Earnings
Exposures Financial
Buy Alert: Regeneron Stock Is Headed Higher
A new delivery method for its COVID-19 treatment may offer a boost. 
Via The Motley Fool
Exposures COVID-19
3 Cathie Wood Healthcare Stocks to Add to Your Portfolio
Despite generating lean capital gains on her holdings in the healthcare industry, Cathie Wood has maintained her positions because she expects genomics to emerge as the next big sector in 2021 that... 
Via Talk Markets
3 Top Coronavirus Stocks to Buy Right Now
Major gains may be on the horizon. 
Via The Motley Fool
Exposures COVID-19
Cathie Wood Loads Up Heavily On Debutant Uipath, Trims Tesla
Cathie Wood-led Ark Investment Management on Wednesday snapped up millions of shares of the New York-based software automation company UiPath Inc (NYSE: PATH) on the day that it... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.